Where Will Madrigal Pharmaceuticals Be in 3 Years?
Madrigal Pharmaceuticals currently has undisputed dominance in its main market. There are powerful actors trying to elbow their way in and change that status.
Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals
Madrigal Pharmaceuticals has a monopoly in its main market -- for the moment. Viking Therapeutics has a good candidate, but it could face powerful competitors.
Is Madrigal Pharmaceuticals Stock a Buy?
Madrigal Pharmaceuticals recently earned an impressive approval from the FDA. The biotech still has work to do to reach its peak potential with this medicine.
Amalgamated Bank Raises Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Amalgamated Bank boosted its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 2.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,119 shares of the biopharmaceutical company’s stock after purchasing an additional 57 shares during the period. Amalgamated Bank’s holdings in Madrigal Pharmaceuticals were worth $490,000 as of its most recent SEC filing. A number of other institutional investors have also recently bought and sold shares of the business. Tower Research Capital LLC TRC boosted its holdings in shares of Madrigal Pharmaceuticals by 21.7% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,060 shares of the biopharmaceutical company’s stock worth $301,000 after buying an additional 367 shares during the last quarter. Glenmede Trust Co. NA boosted its stake in Madrigal Pharmaceuticals by 53.2% in the third quarter. Glenmede Trust Co. NA now owns 1,567 shares of the biopharmaceutical company’s stock valued at $229,000 after acquiring an additional 544 shares during the last quarter. J.P. Morgan Private Wealth Advisors LLC purchased a new position in Madrigal Pharmaceuticals in the third quarter valued at about $314,000. Charles Schwab Investment Management Inc. grew its position in shares of Madrigal Pharmaceuticals by 11.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 109,501 shares of the biopharmaceutical company’s stock valued at $15,992,000 after acquiring an additional 11,083 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Madrigal Pharmaceuticals by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,573,338 shares of the biopharmaceutical company’s stock worth $229,770,000 after purchasing an additional 107,816 shares during the last quarter. Institutional investors own 98.50% of the company’s stock. Madrigal Pharmaceuticals Stock Performance NASDAQ MDGL opened at $220.06 on Monday. The company’s 50 day simple moving average is $234.43 and its two-hundred day simple moving average is $221.25. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.39 and a quick ratio of 9.39. Madrigal Pharmaceuticals, Inc. has a 1 year low of $119.76 and a 1 year high of $302.68. The stock has a market capitalization of $4.69 billion, a PE ratio of -9.53 and a beta of -0.33. Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($7.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.06) by ($1.32). During the same period in the prior year, the firm posted ($4.23) earnings per share. Analysts predict that Madrigal Pharmaceuticals, Inc. will post -27.62 earnings per share for the current fiscal year. Wall Street Analyst Weigh In Several equities analysts have weighed in on the company. StockNews.com raised Madrigal Pharmaceuticals to a “sell” rating in a report on Friday, April 12th. B. Riley cut their price target on Madrigal Pharmaceuticals from $270.00 to $200.00 and set a “neutral” rating for the company in a research note on Friday, May 10th. TD Cowen boosted their price objective on Madrigal Pharmaceuticals from $349.00 to $390.00 and gave the company an “outperform” rating in a research note on Friday, March 15th. UBS Group increased their target price on shares of Madrigal Pharmaceuticals from $337.00 to $410.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $336.00 target price on shares of Madrigal Pharmaceuticals in a research note on Thursday, March 14th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $345.09. Read Our Latest Report on Madrigal Pharmaceuticals Insider Buying and Selling at Madrigal Pharmaceuticals In related news, Director Richard S. Levy sold 11,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $257.48, for a total value of $2,832,280.00. Following the transaction, the director now directly owns 10,298 shares in the company, valued at $2,651,529.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CMO Rebecca Taub sold 2,676 shares of Madrigal Pharmaceuticals stock in a transaction on Monday, April 8th. The shares were sold at an average price of $245.99, for a total transaction of $658,269.24. Following the completion of the sale, the chief marketing officer now directly owns 458,999 shares of the company’s stock, valued at approximately $112,909,164.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard S. Levy sold 11,000 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $257.48, for a total transaction of $2,832,280.00. Following the completion of the transaction, the director now owns 10,298 shares of the company’s stock, valued at $2,651,529.04. The disclosure for this sale can be found here. Insiders have sold a total of 168,985 shares of company stock valued at $36,149,878 in the last 90 days. Corporate insiders own 23.92% of the company’s stock. Madrigal Pharmaceuticals Company Profile (Free Report) Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
